209 related articles for article (PubMed ID: 11921431)
1. Are all glitazones the same?
Van Gaal L; Scheen AJ
Diabetes Metab Res Rev; 2002; 18 Suppl 2():S1-4. PubMed ID: 11921431
[TBL] [Abstract][Full Text] [Related]
2. Promising new approaches.
Reasner CA
Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
[TBL] [Abstract][Full Text] [Related]
3. Pioglitazone and rosiglitazone for diabetes.
Drug Ther Bull; 2001 Sep; 39(9):65-8. PubMed ID: 11586802
[TBL] [Abstract][Full Text] [Related]
4. Repaglinide in combination therapy.
Moses R
Diabetes Nutr Metab; 2002 Dec; 15(6 Suppl):33-8. PubMed ID: 12702006
[TBL] [Abstract][Full Text] [Related]
5. Differentiating members of the thiazolidinedione class: a focus on safety.
Lebovitz HE
Diabetes Metab Res Rev; 2002; 18 Suppl 2():S23-9. PubMed ID: 11921435
[TBL] [Abstract][Full Text] [Related]
6. Differentiating members of the thiazolidinedione class: a focus on efficacy.
Goldstein BJ
Diabetes Metab Res Rev; 2002; 18 Suppl 2():S16-22. PubMed ID: 11921434
[TBL] [Abstract][Full Text] [Related]
7. [Thiazolidinediones--a new class of oral antidiabetics].
Schmitz OE; Brock B; Madsbad S; Beck-Nielsen H
Ugeskr Laeger; 2001 Oct; 163(44):6106-11. PubMed ID: 11715152
[TBL] [Abstract][Full Text] [Related]
8. Pioglitazone.
Lawrence JM; Reckless JP
Int J Clin Pract; 2000 Nov; 54(9):614-8. PubMed ID: 11220991
[TBL] [Abstract][Full Text] [Related]
9. The role of troglitazone in treating the insulin resistance syndrome.
Granberry MC; Schneider EF; Fonseca VA
Pharmacotherapy; 1998; 18(5):973-87. PubMed ID: 9758309
[TBL] [Abstract][Full Text] [Related]
10. Rosiglitazone.
Goldstein BJ
Int J Clin Pract; 2000 Jun; 54(5):333-7. PubMed ID: 10954962
[TBL] [Abstract][Full Text] [Related]
11. [Mechanisms of action of thiazolidinediones].
Girard J
Diabetes Metab; 2001 Apr; 27(2 Pt 2):271-8. PubMed ID: 11452221
[TBL] [Abstract][Full Text] [Related]
12. Thiazolidinediones: a new class of antidiabetic drugs.
Day C
Diabet Med; 1999 Mar; 16(3):179-92. PubMed ID: 10227562
[TBL] [Abstract][Full Text] [Related]
13. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
Khanderia U; Pop-Busui R; Eagle KA
Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
[TBL] [Abstract][Full Text] [Related]
14. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
Mudaliar S; Henry RR
Annu Rev Med; 2001; 52():239-57. PubMed ID: 11160777
[TBL] [Abstract][Full Text] [Related]
15. Troglitazone and related compounds: therapeutic potential beyond diabetes.
Fujiwara T; Horikoshi H
Life Sci; 2000 Oct; 67(20):2405-16. PubMed ID: 11065164
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes.
Blaschke F; Caglayan E; Hsueh WA
Endocrinol Metab Clin North Am; 2006 Sep; 35(3):561-74, ix. PubMed ID: 16959586
[TBL] [Abstract][Full Text] [Related]
17. Thiazolidinediones and liver toxicity.
Scheen AJ
Diabetes Metab; 2001 Jun; 27(3):305-13. PubMed ID: 11431595
[TBL] [Abstract][Full Text] [Related]
18. The mode of action of thiazolidinediones.
Hauner H
Diabetes Metab Res Rev; 2002; 18 Suppl 2():S10-5. PubMed ID: 11921433
[TBL] [Abstract][Full Text] [Related]
19. Pioglitazone, rosiglitazone, and rosiglitazone + metformin: new drugs. Glitazone + oral antidiabetic combination: inadequately evaluated.
Prescrire Int; 2005 Aug; 14(78):133-9. PubMed ID: 16106595
[TBL] [Abstract][Full Text] [Related]
20. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance.
Durbin RJ
Diabetes Obes Metab; 2004 Jul; 6(4):280-5. PubMed ID: 15171752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
